Sina Davari Farid, MD
Pain Medicine · Washington, DCNPI 1386055077
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,834 of the $8,565 with a category attached, or 79.8%. 23 manufacturers reported payments, led by Boston Scientific at 28.5% of the total.
Across 167 payments — averaging $51.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Medtronic$2K
- Abbott$1K
- Nevro Corp.$839
- Vertos Medical, Inc.$344
- SPR Therapeutics, Inc$335
- plus $1K from 17 others
What the payments were for
- Travel & lodging$1,68920%
- Food & beverage$6,83480%
- Education$420%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 40 | $2,443 |
| Medtronic(2 entities) | 49 | $1,850 |
| Abbott | 25 | $1,437 |
| Nevro Corp. | 6 | $839 |
| Vertos Medical, Inc. | 5 | $344 |
| SPR Therapeutics, Inc | 5 | $335 |
| AbbVie | 10 | $252 |
| Stryker | 1 | $237 |
| Biodelivery Sciences International, Inc. | 5 | $186 |
| Painteq LLC | 2 | $161 |
| Acacia Pharma Inc | 1 | $125 |
| Globus Medical | 3 | $58 |
| Hikma Pharmaceuticals USA | 3 | $55 |
| Stratus Medical, LLC | 1 | $44 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Bioventus LLC | 1 | $27 |
| Collegium Pharmaceutical, Inc. | 2 | $26 |
| Amgen | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Almatica Pharma LLC | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Lenoss Medical Inc | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$717
- Senza Spinal Cord Stimulation System$593
- Infinion 16$481
- INTELLIS ADAPTIVESTIM$403
- INCEPTIV$270
- IVS - VERTEBRAL AUGMENTATION PRODUCTS$237
- WaveWriter Alpha Prime 16$170
- KYPHON EXPRESS II KYPHOPAK TRAY$164
- SPRINT PNS System$150
- INTELLIS$146
- mild Device Kit$125
- BYFAVO$125
- BELBUCA$120
- SYNCHROMEDII$116
- SPECTRA WAVEWRITER$115
- GENERAL - THERAPIES$114
How this compares
Too few pain medicine providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 41 | $7,385 |
| BelbucaBuprenorphine Hcl | 19 | $7,306 |
| Xtampza ErOxycodone Myristate | 12 | $5,052 |
| Lidocaine | 30 | $3,080 |
| Gabapentin | 124 | $1,187 |
| Pregabalin | 48 | $716 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 54 | $690 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $608 |
| Celecoxib | 37 | $522 |
| Duloxetine Hcl | 33 | $457 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 57 | $429 |
| Morphine Sulfate ErMorphine Sulfate | 13 | $331 |
| Oxycodone Hcl | 45 | $327 |
| Tizanidine Hcl | 27 | $199 |
| Tramadol Hcl | 55 | $130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $26 | $12,35831 claims |
| Hikma Pharmaceuticals USABuprenorphine | $55 | $7,38541 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pain medicine providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.
Other pain medicine in Washington
- Mehul DesaiWashington$339K
- Geet PaulWashington$18K
- Raissa Quezado da NobregaWashington$16K
- Knell VillartaWashington$8K
- Brent EarlsWashington$7K
- Michael Pitts-KieferWashington$6K
- May ChinWashington$2K
- James PendletonWashington$1K
- Julia FrankWashington$1K
- Navid RashidWashington$352
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.